Marker Therapeutics (NASDAQ:MRKR) Trading Up 8.3% – Here’s What Happened

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) were up 8.3% during mid-day trading on Friday . The stock traded as high as $3.53 and last traded at $3.52. Approximately 17,599 shares were traded during mid-day trading, a decline of 28% from the average daily volume of 24,576 shares. The stock had previously closed at $3.25.

Marker Therapeutics Price Performance

The firm has a 50 day moving average of $3.09 and a 200-day moving average of $3.99.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative return on equity of 78.91%. The firm had revenue of $1.17 million for the quarter. On average, research analysts predict that Marker Therapeutics, Inc. will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. lifted its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the period. Wedbush Securities Inc. owned about 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.